Abstract
Genome-wide studies have identified thousands of noncoding RNAs (ncRNAs) with no protein coding capacity. Among them, the long non-coding RNAs (lncRNAs), which are more than 200 nucleotides in length, recently are widely concerned for their crucial role in regulating biological processes and diseases. However, most lncRNAs are expressed at a very low level, and generally exhibit poor primary sequence conservation over evolution. Long non-coding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), also known as NEAT2 (nuclear-enriched abundant transcript 2), is outstanding among the lncRNA family due to its evolutionarily high conservation and abundant expression throughout diferent mammalian species. Meanwhile, MALAT1 was one of the first lncRNAs that was demonstrated to be associated with a disease, namely non-small cell lung cancer (NSCLC). Subsequently, MALAT1 was identified in multiple types of physiological processes, such as alternative splicing, nuclear organization, epigenetic modulating of gene expression, and so on. Moreover, a growing number of evidences indicated that MALAT1 was also closely related to various pathological processes, ranging from diabetes complications to cancers.In this review, we will make a summary on current understanding of MALAT1 in different physiological or pathophysiological processes and discuss the potential therapeutic applications based on MALAT1 detection and inhibition.
Keywords: Cancer, diseases, gene therapy, long noncoding RNA, MALAT1.
Current Pharmaceutical Design
Title:Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Volume: 21 Issue: 34
Author(s): Yuting Wu, Cheng Huang, Xiaoming Meng and Jun Li
Affiliation:
Keywords: Cancer, diseases, gene therapy, long noncoding RNA, MALAT1.
Abstract: Genome-wide studies have identified thousands of noncoding RNAs (ncRNAs) with no protein coding capacity. Among them, the long non-coding RNAs (lncRNAs), which are more than 200 nucleotides in length, recently are widely concerned for their crucial role in regulating biological processes and diseases. However, most lncRNAs are expressed at a very low level, and generally exhibit poor primary sequence conservation over evolution. Long non-coding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), also known as NEAT2 (nuclear-enriched abundant transcript 2), is outstanding among the lncRNA family due to its evolutionarily high conservation and abundant expression throughout diferent mammalian species. Meanwhile, MALAT1 was one of the first lncRNAs that was demonstrated to be associated with a disease, namely non-small cell lung cancer (NSCLC). Subsequently, MALAT1 was identified in multiple types of physiological processes, such as alternative splicing, nuclear organization, epigenetic modulating of gene expression, and so on. Moreover, a growing number of evidences indicated that MALAT1 was also closely related to various pathological processes, ranging from diabetes complications to cancers.In this review, we will make a summary on current understanding of MALAT1 in different physiological or pathophysiological processes and discuss the potential therapeutic applications based on MALAT1 detection and inhibition.
Export Options
About this article
Cite this article as:
Wu Yuting, Huang Cheng, Meng Xiaoming and Li Jun, Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease, Current Pharmaceutical Design 2015; 21 (34) . https://dx.doi.org/10.2174/1381612821666150724115625
DOI https://dx.doi.org/10.2174/1381612821666150724115625 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology
Current Pharmaceutical Biotechnology Photodynamic Therapy: The Development of New Photosensitisers
Anti-Cancer Agents in Medicinal Chemistry AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy Hypoxia Signaling and the Metastatic Phenotype
Current Molecular Medicine iHyd-PseAAC (EPSV): Identifying Hydroxylation Sites in Proteins by Extracting Enhanced Position and Sequence Variant Feature via Chou's 5- Step Rule and General Pseudo Amino Acid Composition
Current Genomics Computer-Aided Detection System for the Classification of Non-Small Cell Lung Lesions using SVM
Current Computer-Aided Drug Design ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Targeting Angiogenic Genes as a Therapeutic Approach for Hepatocellular Carcinoma
Current Gene Therapy Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design CNS Drug Development – Lost in Translation?
Mini-Reviews in Medicinal Chemistry Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Current Pharmaceutical Design Recent Advances in Pharmacokinetics of Polymeric Excipients Used in Nanosized Anti-Cancer Drugs
Current Drug Metabolism Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Use of Positron Emission Tomography for Target Volume Definition
Current Radiopharmaceuticals Synthesis of Phosphorylated Derivatives of 2', 3'-O-Isopropylidene Adenosine and their In Ovo Antiviral Activity
Letters in Drug Design & Discovery <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism The Role of ABC Transporters in Protecting Cells from Bilirubin Toxicity
Current Pharmaceutical Design Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Current Cancer Therapy Reviews Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery